Assessing AbCellera Biologics (ABCL) Valuation Following Phase 1 Trial Progress and Clinical Milestones [Yahoo! Finance]
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Yahoo! Finance
The company also increased activities at its newly launched clinical production facility. See our latest analysis for AbCellera Biologics. AbCellera's milestone-filled quarter hasn't gone unnoticed by investors, but volatility remains pronounced. After a string of pipeline and executive updates, the stock saw a sharp sell-off and now carries a 1-year total shareholder return of 44.8%, despite a recent 29% dip in share price over the past week. Short-term momentum may be choppy, but the company's transition to a clinical-stage biotech and progress across multiple candidates continues to shape its long-term narrative. Looking to uncover other healthcare innovators making similar leaps? Discover the full range of opportunities with our See the full list for free. With shares trading well below analyst price targets but volatility lingering, the question for investors is clear: is now the moment to buy into AbCellera's next phase or is growth already accounted for? Most Popular
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss [Yahoo! Finance]Yahoo! Finance
- Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? [Yahoo! Finance]Yahoo! Finance
- The Best Canadian Stock You've Never Heard of [Yahoo! Finance Canada]Yahoo! Finance Canada
- AbCellera Appoints Dr. Stephen Quake to its Board of DirectorsBusiness Wire
ABCL
Earnings
- 11/6/25 - Miss
ABCL
Sec Filings
- 11/28/25 - Form 8-K
- 11/26/25 - Form 4
- 11/12/25 - Form 8-K
- ABCL's page on the SEC website